Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Viva BioInnovator

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 23
Average round size
The average size of a deal this fund participated in
Portfolio companies 21
Rounds per year 1.64
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

Viva BioInnovator is the famous VC, which was founded in 2014. The company was established in Asia in China. The leading representative office of defined VC is situated in the Shanghai.

The typical startup value when the investment from Viva BioInnovator is 5-10 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 8 percentage points less often commits exit comparing to other organizations. Deals in the range of 1 - 5 millions dollars are the general things for fund. The top activity for fund was in 2017.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Mebias Discovery, Tabomedex Biosciences, Inc., QurAlis. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Viva BioInnovator, startups are often financed by MP Healthcare Venture Management, Amgen Ventures, Alexandria Venture Investments. The meaningful sponsors for the fund in investment in the same round are Sprout BioVentures, MP Healthcare Venture Management, Lumira Ventures. In the next rounds fund is usually obtained by Kaitai Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Viva BioInnovator:
Typical Co-investors
Viva BioInnovator is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Viva BioInnovator:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Ali Jiankang China, Hebei, Shijiazhuang
Ashoka Arlington, United States, Virginia
Blacksmith Capital California, Palo Alto, United States
Fame Mount Limited -
Huijun Venture Capital China, Shanghai
IMAGE WORKS Japan, Kyoto, Kyoto Prefecture
Jinhuanan Investment China, Futian, Guangdong
Kingson Capital Partners Durban, KwaZulu-Natal, South Africa
Live Shark Tank -
Novelion Therapeutics British Columbia, Canada, Vancouver
Sanari Capital Sandston, United States, Virginia
Savitr Capital California, San Francisco, United States
Scientific Health Development Partners Dallas, Texas, United States
Seneca Creek Ventures Boston, Massachusetts, United States
Stow Capital -
Ulmus Investment -
Zhongmi Capital China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Domain Therapeutics

Health Care
$46M10 May 2022 France, Grand Est, France


Health Care
$20M03 Mar 2022 Princeton, New Jersey, United States

HAYA Therapeutics

Health Care
$5M09 Feb 2022 Lausanne, Vaud, Switzerland

Amberstone Biosciences

Health Care
$12M03 Jan 2022 Laguna Hills, California, United States

Fuse Biotherapeutics

Health Care
$9M15 Nov 2021 Los Angeles, California, United States

Deka Biosciences

Health Care
$20M29 Oct 2021 Washington, District of Columbia, United States

IpiNovyx Bio

$10M05 Oct 2021 New York, New York, United States

Karma Biotechnologies

$2M01 Sep 2021 Los Angeles, California, United States

HAYA Therapeutics

Health Care
$19M20 May 2021 Lausanne, Vaud, Switzerland
HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs

– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.

DTx Pharma Closes $100M Series B Financing

– DTx Pharma, Inc. from San Diego raised $100m in Series B financing.
– The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
– The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Viva BioInnovator?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: